Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Pneumococcal Vaccine in Alefacept-Treated Psoriasis
NCT00493324Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2007
- Primary completion
- Jul 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of alefacept in psoriasis, sponsored by Astellas Pharma. Primary endpoint: The number and percentage of subjects with at least a 2-fold increase in 2 or more of 5 pneumococcal antibody titers at 12 weeks. Started Jul 2007; status: completed.
02
Drugs
alefacept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00493324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493324.